---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-015212"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:42:06.502542+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Clene Q1 net loss $11.1M ($0.09/shr); cash $27.9M; VISIONARY-MS data positive

## Summary
- Cash, equivalents and marketable securities $27.9M at Mar 31, down from $35.0M at Dec 31, 2023; expected to fund operations into Q4 2024.
- Net loss $11.1M ($0.09/shr) vs $11.8M ($0.15/shr) YoY; R&D expenses fell to $5.9M from $7.4M.
- Long-term VISIONARY-MS extension: significant vision improvement (up to 38 letters, p<0.001) and cognition (SDMT +29 points, p<0.001).
- Received $7.3M NIH sub-award for ALS Expanded Access Program; company advancing FDA discussions for NDA filing in H2 2024.
- Peer-reviewed publication in ACS journal characterized CNM-Au8 protein corona supporting neuroprotective mechanism.

## SEC filing metadata
- accession: 0001437749-24-015212
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774924015212/0001437749-24-015212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774924015212/clnn20240202_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-015212
- JSON: https://secwatch.observer/filing/0001437749-24-015212.json
- Plain text: https://secwatch.observer/filing/0001437749-24-015212.txt

## Key facts
- Earnings Releases
  Clene Inc. reported first quarter 2024 results: net income net loss of $11.1 million, EPS $0.09 per share.
  - Period: first quarter 2024
  - Net income: net loss of $11.1 million
  - EPS: $0.09 per share
  - Result: reported results
  source text: Clene reported a net loss of $11.1 million , or $0.09 per share, for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000143774924015212/0001437749-24-015212-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.